SK Bioscience Signs 200 Billion KRW COVID-19 Vaccine Contract with Korea Disease Control and Prevention Agency
[Asia Economy Reporter Hwang Yoon-joo] SK Bioscience announced on the 22nd that it has signed a KRW 200 billion government advance purchase agreement for the COVID-19 vaccine with the Korea Disease Control and Prevention Agency. This amount corresponds to 88.65% of the recent sales revenue.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Jeong Yu-kyung Is a Neighbor"...Itaewon Standalone House with Record 23.2 Billion Won Appraisal Up for Auction [Real Estate AtoZ]
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The company stated, "If the Republic of Korea's approval is not obtained by the end of December 2022 or within an extended period separately agreed upon by the contracting parties, the above contract may be terminated," and added, "The contract period is 24 months from the date of approval and may be extended by mutual agreement of the contracting parties."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
